Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis

被引:0
|
作者
Brunner, Christine
Jaeger, Thomas
Suppan, Christoph
Mueller-Holzner, Elisabeth
Jasarevic, Zerina
Balic, Marija
Goebel, Georg
Marth, Christian
Stoeger, Herbert
Samonigg, Hellmut
Hubalek, Michael
Lang, Alois
机构
[1] Dept Gynecol & Obstet, Innsbruck, Austria
[2] LKH Feldkirch, Feldkirch, Austria
[3] Med Univ Graz, Dept Internal Med, Graz, Austria
[4] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[5] Breast Canc Ctr Vorarlberg, Feldkirch, Austria
[6] Med Univ Graz, Graz, Austria
[7] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Oecon, A-6020 Innsbruck, Austria
[8] Med Univ Graz, Dept Med Oncol, Graz, Austria
[9] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[10] Acad Teaching Hosp, Feldkirch, Austria
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
583
引用
收藏
页数:1
相关论文
共 50 条
  • [31] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Shruti R. Tiwari
    Prasun Mishra
    Paola Raska
    Benjamin Calhoun
    Jame Abraham
    Halle Moore
    G. Thomas Budd
    Alicia Fanning
    Stephanie Valente
    Robyn Stewart
    Stephen R. Grobmyer
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2016, 158 : 189 - 193
  • [32] Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience
    Tiwari, A.
    Gogia, A.
    Deo, S. V. S.
    Shukla, N. K.
    Mathur, S.
    Sharma, D. N.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 343 - 346
  • [33] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Tiwari, Shruti R.
    Mishra, Prasun
    Raska, Paola
    Calhoun, Benjamin
    Abraham, Jame
    Moore, Halle
    Budd, G. Thomas
    Fanning, Alicia
    Valente, Stephanie
    Stewart, Robyn
    Grobmyer, Stephen R.
    Montero, Alberto J.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 189 - 193
  • [34] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
  • [35] Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer
    Zucchini, G.
    Bernardi, A.
    Martoni, A.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 264 - 265
  • [36] Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
    Valabrega, G.
    Montemurro, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 977 - 984
  • [37] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
    K Mann
    M Kullberg
    Cancer Gene Therapy, 2016, 23 : 221 - 228
  • [38] Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
    Noor Al-Dasooqi
    Joanne M. Bowen
    Rachel J. Gibson
    Thomas Sullivan
    Jude Lees
    Dorothy M. Keefe
    Investigational New Drugs, 2009, 27 : 173 - 178
  • [39] Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
    Al-Dasooqi, Noor
    Bowen, Joanne M.
    Gibson, Rachel J.
    Sullivan, Thomas
    Lees, Jude
    Keefe, Dorothy M.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 173 - 178
  • [40] Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    Shattuck, David L.
    Miller, Jamie K.
    Carraway, Kermit L., III
    Sweeney, Colleen
    CANCER RESEARCH, 2008, 68 (05) : 1471 - 1477